Detailed Information

Cited 9 time in webofscience Cited 11 time in scopus
Metadata Downloads

Stereotactic ablative radiotherapy for pulmonary oligometastases from primary hepatocellular carcinoma: a multicenter and retrospective analysis (KROG 17-08)

Authors
Jo, In YoungPark, Hee ChulKim, Eun SeogYeo, Seung-GuKim, MyungsooSeong, JinsilKim, Jun WonKim, Tae HyunYoon, Won SupJeong, Bae KwonKim, Sung HwanLee, Jong Hoon
Issue Date
31-May-2022
Publisher
Oxford University Press
Keywords
hepatocellular carcinoma; pulmonary metastasis; radiotherapy; response
Citation
Japanese Journal of Clinical Oncology, v.52, no.6, pp 616 - 622
Pages
7
Indexed
SCIE
SCOPUS
Journal Title
Japanese Journal of Clinical Oncology
Volume
52
Number
6
Start Page
616
End Page
622
URI
https://scholarworks.gnu.ac.kr/handle/sw.gnu/1256
DOI
10.1093/jjco/hyac028
ISSN
0368-2811
1465-3621
Abstract
Objective: Hypofractionated radiotherapy has recently been applied to treat pulmonary metastases of hepatocellular carcinoma. However, there is no definite evidence on its safety and efficacy. We evaluate the clinical outcomes of hypofractionated radiotherapy for oligo pulmonary metastases of hepatocellular carcinoma in the multicenter and retrospective study. Methods: From March 2011 to February 2018, 58 patients with fewer than five pulmonary metastases of hepatocellular carcinoma who underwent hypofractionated radiotherapy in nine tertiary university hospitals were analyzed retrospectively. The primary endpoint was the local control rate. The secondary endpoints were overall survival, progression-free survival, prognostic factors affecting the treatment outcomes and treatment-related side effects. Results: The local tumor response rate including complete and partial response was 77.6% at 3 months after hypofractionated radiotherapy. The median survival and progression-free survival times were 20.9 and 5.3 months, respectively. The 1-year overall survival and progression-free survival rates were 65.5 and 22.4%, respectively. The good treatment response after hypofractionated radiotherapy (P = 0.001), the absence of intrahepatic tumor (P = 0.004) and Child-Pugh class A (P = 0.010) were revealed as significant prognostic factors for overall survival in the multivariate analysis. A progression-free interval of <6 months (P = 0.009) was a negative prognostic factor for overall survival in the multivariate analysis. Of 58 patients, five (8.6%) had grade 2 or higher radiation pneumonitis after hypofractionated radiotherapy. Conclusions: The favorable local control rate and acceptable toxicity indicate the clinical usefulness of hypofractionated radiotherapy for hepatocellular carcinoma patients who have less than five pulmonary metastases.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medicine > Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Jeong, Bae Kwon photo

Jeong, Bae Kwon
의과대학 (의학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE